Article
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1.
Nature - 5 Nov 2009
Barbie David A, Tamayo Pablo, Boehm Jesse S, Kim So Young, Moody Susan E, Dunn Ian F, Schinzel Anna C, Sandy Peter, Meylan Etienne, Scholl Claudia, Fröhling Stefan, Chan Edmond M, Sos Martin L, Michel Kathrin, Mermel Craig, Silver Serena J, Weir Barbara A, Reiling Jan H, Sheng Qing, Gupta Piyush B, Wadlow Raymond C, Le Hanh, Hoersch Sebastian, Wittner Ben S, Ramaswamy Sridhar, Livingston David M, Sabatini David M, Meyerson Matthew, Thomas Roman K, Lander Eric S, Mesirov Jill P, Root David E, Gilliland D Gary, Jacks Tyler, Hahn William C
Abstract excerpt
The proto-oncogene KRAS is mutated in a wide array of human cancers, most of which are aggressive and respond poorly to standard therapies. Although the identification of specific oncogenes has led to the development of clinically effective, molecularly targeted therapies in some cases, KRAS has remained refractory to this approach. A complementary strategy for targeting KRAS is to identify gene products that,...
Topics
Join the communities discussing this publication.